Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Patients with esophageal squamous cell carcinoma (ESCC) have an unmet need for new therapies that improve survival. In this phase II trial, patients received ociperlimab and tislelizumab (A) or placebo and tislelizumab (B) (NCT04732494). The primary endpoint was objective response rate (ORR) assessed by the investigator per RECIST v1.1. A total of 125 patients were randomized to A (N = 62) and B (N = 63).
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.